A Look at Nektar’s Recent Collaboration with Isoplexis

On June 26, Isoplexis, a privately held life sciences company, and Nektar Therapeutics, announced a collaboration focused on the functional impact of Nektar’s NKTR-214 in the clinical setting at the single-cell level with the aim to reveal the mechanism and potential immune correlation with the outcome. The collaboration aims to employ Isoplexis’s IsoCode Chip’s single-cell functional profiling for profiling the effects of Nektar’s NKTR-214 drug in both monotherapy and combination treatments in a clinical setting. IsoPlexis’s chief executive officer, Sean Mackay, said, “We are excited to collaborate with Nektar Therapeutics and further demonstrate the broad impact of NKTR-214 and its ability to induce critical T cell responses in cancer immunotherapy.